February 13, 2013 / 7:15 AM / 5 years ago

Reckitt Benckiser beats earnings forecasts

LONDON, Feb 13 (Reuters) - Britain’s Reckitt Benckiser beat full-year earning expectations as the maker of Strepsils and Mucinex benefited from an unusually heavy U.S. cold and flu season in the final quarter.

Full-year adjusted earnings per share was 264.4 pence, compared to Thomson Reuters I/B/E/S estimates of 246.8 pence and a company-supplied forecast of 249 pence.

An early and unusually intense flu season in North America has pushed up business for hospitals, pharmacies and the makers of tissues and cold remedies.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below